Kimberly Jones
Nurse Practitioner · Round Rock, TXNPI 1811483589
Payments from drug & device makers
Across 101 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$485
- Lilly USA, LLC$218
- Xeris Pharmaceuticals, Inc.$132
- Boehringer Ingelheim$105
- Dexcom, Inc.$75
- Novo Nordisk$59
- plus $740 from 22 others
What the payments were for
- Food & beverage$1,80199%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $485 |
| Lilly USA, LLC | 11 | $218 |
| Xeris Pharmaceuticals, Inc. | 6 | $132 |
| Boehringer Ingelheim | 5 | $105 |
| Dexcom, Inc. | 4 | $75 |
| Novo Nordisk | 3 | $59 |
| Amgen(2 entities) | 3 | $59 |
| AstraZeneca | 3 | $55 |
| Recordati_rare_diseases_inc. | 2 | $50 |
| Alvogen Inc | 2 | $50 |
| IBSA Pharma Inc. | 3 | $49 |
| Radius Health, Inc. | 2 | $48 |
| Amphastar Pharmaceuticals, Inc. | 2 | $46 |
| Antares Pharma, Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $40 |
| Insulet Corporation | 2 | $35 |
| Tandem Diabetes Care, Inc. | 2 | $34 |
| Bayer | 2 | $33 |
| Astellas Pharma US Inc | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Tolmar, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| Mannkind Corporation | 1 | $13 |
How this compares
$1,813 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 344 | $424,213 |
| OzempicSemaglutide | 287 | $343,974 |
| JardianceEmpagliflozin | 86 | $106,176 |
| Tresiba Flextouch U-100Insulin Degludec | 97 | $77,910 |
| TrulicityDulaglutide | 46 | $68,450 |
| FarxigaDapagliflozin Propanediol | 36 | $51,293 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $40,580 |
| TradjentaLinagliptin | 36 | $36,665 |
| JanuviaSitagliptin Phosphate | 39 | $34,983 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $34,229 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $30,783 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $27,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $25,870 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $22,561 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $20,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $218 | $492,663390 claims |
| Novo NordiskOzempic, Rybelsus | $59 | $361,543305 claims |
| Boehringer IngelheimJardiance, Tradjenta | $105 | $142,841122 claims |
| AstraZenecaFarxiga | $55 | $51,29336 claims |
| Sanofi-aventis U.S. LLCLantus | $19 | $1,63116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Round Rock
- Stephanie AgrellaRound Rock$102K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.